Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2018,（6）
• 页码范围: 561-566
• 页数: 6页
• 语种: 英文

摘要

We aimed to investigate the prognostic value of chromogranin A (CgA) in castration-resistant prostate cancer (CRPC).We conducted a systematic literature search of PubMed,Web of Science,and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard meta-analysis on survival outcomes.Our meta-analysis included eight eligible studies with 686 patients.The results were as follows:progression-free survival (PFS) was associated with CgA level (hazard ratio [HR] =2.47,95％ confidence interval [CI]:1.47-4.14,P=0.0006);PFS was relative to CgA change (HR =9.22,95％ CI.:3.03-28.05,P＜ 0.0001);and overall survival (OS) was relative to CgA level (HR =1.47,95％ CI:1.15-1.87,P=0.002).When we divided the patients into two groups according to therapy status,the result for OS relative to CgA level was an HR of 1.26 (95％ CI:1.09-1.45,P =0.001) in the first-line hormonal therapy group,and an HR of 2.33 (95％ CI:1.40-3.89,P =0.001) in the second-line hormonal therapy or chemotherapy group.This meta-analysis indicated that a high CgA level had a negative influence on OS and PFS in CRPC patients.In addition,CRPC patients with a rising CgA had a shorter PFS.Further studies are needed to verify the prognostic value of CgA in CRPC.